Laura Carzaniga

Dr. Laura Carzaniga

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
NMNadia Moretto
Nadia Moretto
PCPaola Caruso
Paola Caruso
RBRaffaella Bosco
Raffaella Bosco
GMGessica Marchini
Gessica Marchini
FPFiorella Pastore
Fiorella Pastore
FFFabrizio Facchinetti
Fabrizio Facchinetti
This study examined the pharmacologic characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration. CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, respectively, in inhibiting PDE4 enzymatic activity (IC50 = 0.026 ± 0.006 nM). CHF6001 inhibited PDE4 isoforms A–D with equal potency, showed an elevated ratio of high-affinity rolipram binding site versus low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity versus PDE4 compared with a panel of PDEs. CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383). Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells. In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide]. When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.). In sum, CHF6001 has the potential to be an effective topical treatment of conditions associated with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.

1 December 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RSRebecca M. Steele
Rebecca M. Steele
FBFrancesca Benedini
Francesca Benedini
SBStefano Biondi
Stefano Biondi
VBValentina Borghi
Valentina Borghi
LCLaura Carzaniga
Laura Carzaniga
Claudiu SupuranClaudiu Supuran
Claudiu Supuran

29 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EAElisabetta Armani
Elisabetta Armani
GAGabriele Amari
Gabriele Amari
ARAndrea Rizzi
Andrea Rizzi
RFRenato De Fanti
Renato De Fanti
EGEleonora Ghidini
Eleonora Ghidini
GVGino Villetti
Gino Villetti

14 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LCLaura Carzaniga
Laura Carzaniga
GAGabriele Amari
Gabriele Amari
ARAndrea Rizzi
Andrea Rizzi
CCCarmelida Capaldi
Carmelida Capaldi
RFRenato De Fanti
Renato De Fanti
EAElisabetta Armani
Elisabetta Armani

28 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LCLaura Carzaniga
Laura Carzaniga
ILIan D. Linney
Ian D. Linney
ARAndrea Rizzi
Andrea Rizzi
MDMaurizio Delcanale
Maurizio Delcanale
WSWolfgang Schmidt
Wolfgang Schmidt
FRFabio Rancati
Fabio Rancati

5 December 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PBPaolo Bruno
Paolo Bruno
DPDaniele Pala
Daniele Pala
AMAlessandra Micoli
Alessandra Micoli
MCMauro Corsi
Mauro Corsi
AAAlessandro Accetta
Alessandro Accetta
ACAnna Maria Capelli
Anna Maria Capelli